4.6 Article

Site-Specific Proteolytic Cleavage of the Amino Terminus of Herpes Simplex Virus Glycoprotein K on Virion Particles Inhibits Virus Entry

Journal

JOURNAL OF VIROLOGY
Volume 85, Issue 24, Pages 12910-12918

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.06268-11

Keywords

-

Categories

Funding

  1. National Institutes of Health (NIH) [AI43000]
  2. National Institute of Allergy and Infectious Diseases
  3. Core Laboratories
  4. NIH National Center for Research Resources [P20 RR020159]

Ask authors/readers for more resources

Herpes simplex virus 1 (HSV-1) glycoprotein K (gK) is expressed on virions and functions in entry, inasmuch as HSV-1(KOS) virions devoid of gK enter cells substantially slower than is the case for the parental KOS virus (T. P. Foster, G. V. Rybachuk, and K. G. Kousoulas, J. Virol. 75:12431-12438, 2001). Deletion of the amino-terminal 68-amino-acid (aa) portion of gK caused a reduction in efficiency and kinetics of virus entry similar to that of the gK-null virus in comparison to the HSV-1(F) parental virus. The UL20 membrane protein and gK were readily detected on double-gradient-purified virion preparations. Immuno-electron microscopy confirmed the presence of gK and UL20 on purified virions. Coimmunoprecipitation experiments using purified virions revealed that gK interacted with UL20, as has been shown in virus-infected cells (T. P. Foster, V. N. Chouljenko, and K. G. Kousoulas, J. Virol. 82:6310-6323, 2008). Scanning of the HSV-1(F) viral genome revealed the presence of a single putative tobacco etch virus (TEV) protease site within gD, while additional TEV predicted sites were found within the UL5 (helicase-primase helicase subunit), UL23 (thymidine kinase), UL25 (DNA packaging tegument protein), and UL52 (helicase-primase primase subunit) proteins. The recombinant virus gD Delta TEV was engineered to eliminate the single predicted gD TEV protease site without appreciably affecting its replication characteristics. The mutant virus gK-V5-TEV was subsequently constructed by insertion of a gene sequence encoding a V5 epitope tag in frame with the TEV protease site immediately after gK amino acid 68. The gK-V5-TEV, R-gK-V5-TEV (revertant virus), and gD Delta TEV viruses exhibited similar plaque morphologies and replication characteristics. Treatment of the gK-V5-TEV virions with TEV protease caused approximately 32 to 34% reduction of virus entry, while treatment of gD Delta TEV virions caused slightly increased virus entry. These results provide direct evidence that the gK and UL20 proteins, which are genetically and functionally linked to gB-mediated virus-induced cell fusion, are structural components of virions and function in virus entry. Site-specific cleavage of viral glycoproteins on mature and fully infectious virions utilizing unique protease sites may serve as a generalizable method of uncoupling the roles of viral glycoproteins in virus entry and virion assembly.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes

David Bernstein, Derek A. Pullum, Rhonda D. Cardin, Fernando J. Bravo, David A. Dixon, Konstantin G. Kousoulas

VACCINE (2019)

Article Veterinary Sciences

Factors Affecting Growth Kinetics and Spontaneous Metastasis in the B16F10 Syngeneic Murine Melanoma Model

Natalie Fowlkes, Kelli Clemons, Paul J. F. Rider, Ramesh Subramanian, Nobuko Wakamatsu, Ingeborg Langohr, Konstantin G. Kousoulas

COMPARATIVE MEDICINE (2019)

Article Multidisciplinary Sciences

Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials

David I. Bernstein, Rhonda D. Cardin, Derek A. Pullum, Fernando J. Bravo, Konstantin G. Kousoulas, David A. Dixon

PLOS ONE (2019)

Article Cell Biology

Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models

Jean Christopher Chamcheu, Stephane Esnault, Vagar M. Adhami, Andrea L. Noll, Sergette Banang-Mbeumi, Tithi Roy, Sitanshu S. Singh, Shile Huang, Konstantin G. Kousoulas, Hasan Mukhtar

CELLS (2019)

Article Genetics & Heredity

Genomic analysis for virulence determinants in feline herpesvirus type-1 isolates

Andrew C. Lewin, Lyndon M. Coghill, Gillian J. McLellan, Ellison Bentley, Konstantin G. Kousoulas

VIRUS GENES (2020)

Article Multidisciplinary Sciences

Identification and Visualization of Functionally Important Domains and Residues in Herpes Simplex Virus Glycoprotein K(gK) Using a Combination of Phylogenetics and Protein Modeling

Paul J. F. Rider, Lyndon M. Coghill, Misagh Naderi, Jeremy M. Brown, Michal Brylinski, Konstantin G. Kousoulas

SCIENTIFIC REPORTS (2019)

Article Multidisciplinary Sciences

Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1 (F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis

Shan K. Naidu, Rafiq Nabi, Nagarjuna R. Cheemarla, Brent A. Stanfield, Paul J. Rider, Nithya Jambunathan, Vladimir N. Chouljenko, Renee Carter, Fabio Del Piero, Ingeborg Langohr, Konstantin G. Kousoulas

PLOS ONE (2020)

Article Virology

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections

Farhana Musarrat, Vladimir Chouljenko, Achyut Dahal, Rafiq Nabi, Tamara Chouljenko, Seetharama D. Jois, Konstantin G. Kousoulas

JOURNAL OF MEDICAL VIROLOGY (2020)

Article Virology

Cellular and Viral Determinants of Herpes Simplex Virus 1 Entry and Intracellular Transport toward the Nuclei of Infected Cells

Farhana Musarrat, Vladimir Chouljenko, Konstantin G. Kousoulas

Summary: Herpes simplex virus 1 utilizes cellular motor proteins and kinase pathways for intracellular virion transport, with Akt and kinase C inhibitors blocking virus entry and virion capsid transport. UL37 and Vp5 viral proteins are crucial for dynein-dependent transport of virion capsids, while Akt and kinase C do not directly phosphorylate or activate dynein during infection.

JOURNAL OF VIROLOGY (2021)

Article Biochemistry & Molecular Biology

Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers

Tithi Roy, Samuel T. Boateng, Sergette Banang-Mbeumi, Pankaj K. Singh, Pratik Basnet, Roxane-Cherille N. Chamcheu, Federico Ladu, Isabel Chauvin, Vladimir S. Spiegelman, Ronald A. Hill, Konstantin G. Kousoulas, Bolni Marius Nagalo, Anthony L. Walker, Jean Fotie, Siva Murru, Mario Sechi, Jean Christopher Chamcheu

Summary: Novel flavonol-based derivatives targeting skin cancers were synthesized and characterized, showing significant inhibitory effects on human skin cancer cell lines. These compounds were found to induce apoptosis of cancer cells by regulating key molecular targets, presenting promising therapeutic potential for melanoma and non-melanoma skin cancers.

BIOORGANIC CHEMISTRY (2021)

Article Virology

Development of a reliable bovine neuronal cell culture system and labeled recombinant bovine herpesvirus type-1 for studying virus-host cell interactions

Jared S. Rudd, Farhana Musarrat, Konstantin G. Kousoulas

Summary: BoHV-1 infects bovine-derived neuronal cells and can be efficiently studied using FBBC-1 cells. The study provides insights into virus entry and spread mechanisms in a neuronal cell culture system.

VIRUS RESEARCH (2021)

Review Virology

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment

Ifeanyi Kingsley Uche, Konstantin G. Kousoulas, Paul J. F. Rider

Summary: The development of cancer disrupts anti-tumor immunity needed for surveillance and elimination of tumor cells, with immunotherapy aiming to restore or establish these responses. However, a significant proportion of patients do not respond equally to immunotherapies, partially due to the immunosuppressive tumor microenvironment. Current research focuses on mechanisms of immunosuppression in the TME, with the goal of promoting anti-tumor immune responses.

VIRUSES-BASEL (2021)

Article Multidisciplinary Sciences

Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation

Tithi Roy, Samuel T. Boateng, Sergette Banang-Mbeumi, Pankaj K. Singh, Pratik Basnet, Roxane-Cherille N. Chamcheu, Federico Ladu, Isabel Chauvin, Vladimir S. Spiegelman, Ronald A. Hill, Konstantin G. Kousoulas, Bolni Marius Nagalo, Anthony L. Walker, Jean Fotie, Siva Murru, Mario Sechi, Jean Christopher Chamcheu

Summary: This study identifies a panel of novel fisetin analogs that may be developed as potential therapeutic agents for melanoma and non-melanoma skin cancers, providing in-depth biological characterization data to support further research and experimental screening.

DATA IN BRIEF (2021)

Article Virology

Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model

Ifeanyi Kingsley Uche, Natalie Fowlkes, Luan Vu, Tatiane Watanabe, Mariano Carossino, Rafiq Nabi, Fabio del Piero, Jared S. Rudd, Konstantin G. Kousoulas, Paul J. F. Rider

Summary: Oncolytic virotherapy (OVT) uses viral infection to release tumor antigens, promoting antitumor immune responses. VC2, a modified herpes simplex virus, shows clinical potential in a mouse melanoma model and may be an effective treatment for human and animal cancers.

JOURNAL OF VIROLOGY (2021)

Article Microbiology

Anti-viral Immunity in the Tumor Microenvironment: Implications for the Rational Design of Herpes Simplex Virus Type 1 Oncolytic Virotherapy

Paul J. F. Rider, Ifeanyi K. Uche, Larissa Sweeny, Konstantin G. Kousoulas

CURRENT CLINICAL MICROBIOLOGY REPORTS (2019)

No Data Available